Antibodies · 2013 · 148 citations · 217 references
PharmacyMolecular PharmaceuticsPharmaceuticsAntibody EngineeringImmunotechnologyMonoclonal AntibodiesAntibody CharacterizationAntibody ConjugatesAntibody StabilityAntibody-drug ConjugatesBispecific AntibodiesMonoclonal Antibody TherapyAntibody-drug Conjugate BispecificsBispecific Antibody ConjugatesHigh-concentration FormulationsManufacturingManufacturing Of Bispecific AntibodiesMonoclonal Antibody CharacterizationMonoclonal Antibody TherapeuticsStabilization
The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed.
217
Continuous cultures of fused cells secreting antibody of predefined specificity
Georges Köhler, César Milstein · Nature · 1975 · 17.2K citations
Pharmacy, Cell Biology, Immunology +11
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15
Phage antibodies: filamentous phage displaying antibody variable domains
John McCafferty, Andrew D. Griffiths, Greg Winter et al. · Nature · 1990 · 2.4K citations